| Vol. 12.03 – 26 January, 2021 |
| |
|
|
| Using diverse pre-clinical models, the authors investigated the role of interferon regulatory factor 4 (IRF4) in myeloma progenitor regeneration. [Cell Stem Cell] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists describe Tracking Recombination Alleles in Clonal Engraftment using sequencing (TRACE-Seq), a methodology that utilizes barcoded AAV6 donor template libraries, carrying in-frame silent mutations or semi-randomized nucleotides outside the coding region, to track the in vivo lineage contribution of gene-targeted hematopoietic stem and progenitor cell clones. [Nature Communications] |
|
|
|
| Extensive functional assays demonstrated that HBBP1 was essential for erythropoiesis by binding the RNA-binding protein, HNRNPA1, to upregulate TAL1, a key regulator of erythropoiesis. [Developmental Cell] |
|
|
|
| Investigators developed a one‐size‐fits‐all editing strategy for effective T‐cell correction, selection, and depletion and investigated the therapeutic potential of T‐cell and hematopoietic stem/progenitor cell therapies in the hyper‐IgM syndrome mouse model. [EMBO Molecular Medicine] |
|
|
|
| The authors identified CD93 as an important regulator of self-renewal and proliferation of murine and human leukemia stem cells, but not HSCs. [Cell Reports] |
|
|
|
| Comparative whole-genome and whole-transcriptome sequencing analyses of FACS-purified pre-leukemia stem cells from myeloproliferative neoplasm patients revealed APOBEC3C upregulation, an increased C-to-T mutational burden, and hematopoietic stem and progenitor cell proliferation during progression, which could be recapitulated by lentiviral APOBEC3C overexpression. [Cell Reports] |
|
|
|
| Scientists found that SUMOylation of the M2 isoform of pyruvate kinase, a rate-limiting glycolytic enzyme catalyzing the dephosphorylation of phosphoenolpyruvate to pyruvate, was prevalent in a variety of leukemic cell lines as well as primary samples from patients with leukemia through multiple-reaction monitoring based targeted mass spectrometry analysis. [Cell Death & Disease] |
|
|
|
| The authors analyzed the expression of erythroferrone and growth/differentiation factor 15 in CD71+ erythroid progenitors of 111 myelodysplastic syndrome patients and assessed their effects on patient survival. [British Journal of Haematology] |
|
|
|
| Scientists found that lead (Pb)-increased quiescence of HSCs critically relied on a synergetic action of Pb and IFNγ on bone marrow-resident macrophages, but not a direct action of Pb on HSCs. [Toxicological Sciences] |
| |
|
|
| Investigators retrospectively reviewed marrow harvests at their institution performed between 2009 and 2019. During this time, an intraoperative total nucleated cell count was measured after 50% of the projected final graft volume was collected. [Pediatric Blood & Cancer] |
|
|
|
|
| The authors summarize the current knowledge regarding the models and functions of cofactor–transcription factor interplay in physiological hematopoiesis and highlight their implications in the etiology of hematological malignancies. [Signal Transduction and Targeted Therapy] |
|
|
|
| Scientists discuss the latest culture techniques and technological approaches to obtain functional platelets and erythrocytes ex vivo. [Haematologica] |
|
|
|
| Researchers present evidence of the key role of the bone marrow niche in suppressing HSCs during leukemic progression and provide perspectives on how future research in this topic may be exploited to provide treatments for one of the key complications of acute myeloid leukemia. [Experimental Hematology] |
|
|
|
|
| AzurRx BioPharma, Inc announced the activation of two additional clinical trial sites in Poland for the extension arm of the Phase IIb OPTION 2 study investigating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. [AzurRx BioPharma, Inc.] |
|
|
|
|
| March 1 – 2, 2021 Virtual |
|
|
|
|
|
| The University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| STEMCELL Technologies, Inc. – Burnaby, British Columbia, Canada |
|
|
|
| St. Jude Children’s Hospital – Memphis, Tennessee, United States |
|
|
|
| Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
| The Jackson Laboratory – Bar Harbor, Maine, United States |
|
|
|
|